Carisma Therapeutics, Inc. (CARM)
Market Cap | 94.03M |
Revenue (ttm) | 10.63M |
Net Income (ttm) | -73.50M |
Shares Out | 40.36M |
EPS (ttm) | -3.75 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 97,467 |
Open | 2.370 |
Previous Close | 2.320 |
Day's Range | 2.250 - 2.430 |
52-Week Range | 1.960 - 9.766 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 10.75 (+373.57%) |
Earnings Date | May 9, 2024 |
About CARM
Carisma Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, P... [Read more]
Financial Performance
In 2022, CARM's revenue was $40.00 million, an increase of 50.69% compared to the previous year's $26.54 million. Losses were -$19.88 million, 5817.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CARM stock is "Strong Buy." The 12-month stock price forecast is $10.75, which is an increase of 373.57% from the latest price.
News
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
PHILADELPHIA , Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PHILADELPHIA , Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerabi...
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting First patient expected to be treated in the first half of 2024 PHILADELPHIA , Nov. 28, 2023 /PRNewswire/ -- Caris...
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
PHILADELPHIA , Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-m...
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
- Data demonstrate feasibility, tolerability, and early efficacy of mRNA/LNP in vivo CAR-M therapy in pre-clinical models of metastatic solid tumors - Proof of concept achieved for platform under the ...
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data abstracts highlighting next-generation enhancement...
Carisma Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit
Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508 New translational analyses combining group 1 & group 2 continue to support CAR-M...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023
PHILADELPHIA , Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing inn...
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of...
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA® PHILADELPHIA , June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM...
Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes
PHILADELPHIA , June 26, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn...
Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources
These new appointments expand the leadership team to support its legal and human resource sectors to ensure compliance and high quality employee experience PHILADELPHIA , June 14, 2023 /PRNewswire/ --...
Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023
PHILADELPHIA , June 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inno...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023
PHILADELPHIA , May 30, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing inno...
Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights
Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Expanded clinical manufacturing capacity through successful tec...
Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference
PHILADELPHIA , May 8, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innov...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023
PHILADELPHIA , May 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunothera...
Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting
PHILADELPHIA, April 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, anno...
Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023
PHILADELPHIA , April 6, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, toda...
Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights
Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol "CARM" Cash position as of the closing of the merger with Sesen Bio provides anticipated operating runway through 2024 ...
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pending merge...
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update. Business Upda...